Lumipulse® G KL-6 (Krebs von den Lungen)
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
You will find more resources about ILDs and the KL-6 biomarker in our dedicated microsite at www.fujirebio.com/kl-6 (opens in a new window).
Product number 234594
Product number 234600
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Citations
- Documentation
- Insights
- FAQ
- Product inquiry
- Related products
-
Details
See the LUMIPULSE G1200 working in this video:
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Citations
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Other documents
FileKL-6 Whitepaper (pdf, 378.50 kb)Extra informationGuidance document on the value of measuring KL-6 in the field of lung diseases.FileKL-6 Biomarker Information - Physician Leaflet (pdf, 3.71 mb)FileLumipulse G Lung Disease Management brochure (pdf, 151.32 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Jan 6, 2022[Jan 2022 Update] This scientific literature overview demonstrates the excellent performance of the fully automated nucleocapsid protein antigen assay Lumipulse® G SARS-CoV-2 Ag
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
...
Oct 15, 2020Webinar: Lumipulse® G KL-6, the biomarker for routinely assessment of epithelial alveolar damage in pulmonary fibrosis and COVID-19
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Aug 26, 2020Japanese authorities have chosen Lumipulse® for nasopharyngeal or saliva-based SARS-CoV-2 antigen testing of passengers at their main international airports
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Product inquiry
-
Related products